Adjuvance Technologies, Inc. is a privately owned biopharmaceutical company dedicated to empowering global health through fundamental breakthroughs in vaccine adjuvant design and manufacturing. We are commercializing synthetic methods of producing the world’s leading adjuvant molecule and developing a portfolio of novel vaccine adjuvants using our proprietary technology.
Saponex is Adjuvance’s synthetic version of QS-21. Unlike the natural product, Saponex only contains the two molecules responsible for QS-21’s immunostimulatory activity (QS-21-apiose and QS-21-xylose). Unlike natural QS-21, we can use our synthetic technology to control the isomeric constituency of Saponex, providing a customizable, impeccably pure product.
Adjuvance’s TriSST platform is an innovative technology whose superiority provides the power, dependability and adaptability necessary to empower current-generation and next-generation vaccine formulations through our Saponex and TiterQuil molecules.